GT Biopharma, Inc.: GT Biopharma Reports Second Quarter 2026 Financial Results
GT Biopharma (NASDAQ: GTBP) reported Q2 2026 results for the quarter ended June 30, 2026. It said Phase 1 TriKE candidates GTB-3650 (CD33+ leukemias) and GTB-5550 (B7-H3+ solid tumors) are enrolling, with updates expected in 2H 2026. Cash was about $5.1M, funding through Q4 2026. Q2 R&D was ~$1.1M, SG&A ~$3.4M, and net loss ~$4.5M.
How this was made
The 30-second read
Why it matters
The article provides updated financials (cash balance, expense changes) and operational milestones (Phase 1 enrollment status and expected 2H 2026 updates), which can shift probability-weighted timelines and financing risk.
Market read
For traders, the actionable elements are the updated cash runway through Q4 2026 and the stated expectation of additional clinical updates in 2H 2026, tied to ongoing Phase 1 enrollment.
What to watch
The release highlights increased SG&A and R&D costs but does not quantify net cash burn rate or provide updated guidance beyond runway, which may matter for near-term financing expectations.
Background
GT Biopharma is a clinical-stage immuno-oncology company developing TriKE NK cell engager candidates GTB-3650 and GTB-5550.
Ticker impact
GT Biopharma reports Q2 2026 results and says two TriKE candidates are actively enrolling, with updates expected in 2H 2026.
Likely modest, sentiment-driven reaction unless investors focus on the specific 2H 2026 clinical updates and cash burn trajectory.
This is a clinical-stage biotech update with no new efficacy/safety datapoints, but it does provide fresh operational milestones (enrollment status) and updated financial runway.
Market effects
Reinforces ongoing investor focus on NK engager platforms and subcutaneous nanobody dosing feasibility in early-stage oncology.
No clear regional spillover beyond US small-cap biotech sentiment.
Limited, as the catalysts are company-specific clinical enrollment and internal funding runway.
Counterpoint
Enrollment progress and cash runway may not offset dilution risk if SG&A and R&D burn remain elevated before meaningful clinical readouts.
Key entities
- companyGT Biopharma, Inc.
NASDAQ-listed clinical-stage immuno-oncology company developing TriKE NK cell engager therapeutics.
- pipeline_assetGTB-3650 TriKE
Phase 1 dose-escalation candidate for CD33-positive leukemias; Cohort 4 complete and Cohort 5 in progress, update expected in 2H 2026.
- pipeline_assetGTB-5550 TriKE
Phase 1a/1b candidate for B7H3-positive solid tumors using subcutaneous dosing; Cohort 1 complete and Cohort 2 in progress, update expected in 2H 2026.
